-+ 0.00%
-+ 0.00%
-+ 0.00%

Iovance's Lifileucel Shows 50% Response Rate in Soft Tissue Sarcoma Pilot Trial

PUBT·10/26/2026 11:07:05
Listen to the news
Iovance's Lifileucel Shows 50% Response Rate in Soft Tissue Sarcoma Pilot Trial
  • Iovance Biotherapeutics announced pilot trial results showing durable responses to lifileucel in advanced soft tissue sarcomas, presented at ESMO 2026.
  • Tumor shrinkage occurred in refractory undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma; all responses remained ongoing at the September 9, 2026, cutoff.
  • The safety profile was consistent with the lifileucel treatment regimen in other indications.
  • The FDA granted lifileucel fast track designation for both cancers in the second quarter of 2026.
  • Enrollment is underway in the SARATOGA registrational study to support potential approvals in both cancers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260700PRIMZONEFULLFEED9852689) on October 26, 2026, and is solely responsible for the information contained therein.